United Therapeutics (NASDAQ:UTHR) CFO James Edgemond Sells 10,000 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $546.28, for a total value of $5,462,800.00. Following the completion of the transaction, the chief financial officer owned 18,876 shares in the company, valued at approximately $10,311,581.28. The trade was a 34.63% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

James Edgemond also recently made the following trade(s):

• On Monday, June 1st, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $547.87, for a total value of $5,478,700.00.
• On Thursday, May 28th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $565.63, for a total value of $5,656,300.00.
• On Tuesday, May 26th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $572.94, for a total value of $5,729,400.00.
• On Thursday, May 21st, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $564.11, for a total value of $5,641,100.00.
• On Monday, May 18th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $567.31, for a total value of $5,673,100.00.
• On Thursday, May 14th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $574.47, for a total value of $5,744,700.00.
• On Monday, May 11th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $573.03, for a total value of $5,730,300.00.
• On Thursday, May 7th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $578.58, for a total value of $5,785,800.00.
• On Monday, May 4th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $576.93, for a total value of $5,769,300.00.
• On Thursday, April 30th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $572.61, for a total value of $5,726,100.00.

United Therapeutics Stock Performance

Shares of UTHR opened at $549.87 on Friday. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $609.35. The business’s fifty day moving average is $568.23 and its 200-day moving average is $518.83. The firm has a market cap of $23.34 billion, a price-to-earnings ratio of 20.30, a PEG ratio of 1.78 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. During the same quarter in the previous year, the business posted $6.63 EPS. The company’s revenue for the quarter was down 1.6% on a year-over-year basis. As a group, research analysts forecast that United Therapeutics Corporation will post 26.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

UTHR has been the topic of several recent research reports. HC Wainwright raised their price objective on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a report on Tuesday, March 31st. Morgan Stanley set a $516.00 price objective on United Therapeutics in a report on Thursday, May 7th. Oppenheimer raised their price objective on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. UBS Group raised their price objective on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a report on Thursday, March 5th. Finally, Cantor Fitzgerald raised their price objective on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a report on Thursday, March 12th. Eleven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $619.42.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of UTHR. Geneos Wealth Management Inc. lifted its holdings in United Therapeutics by 141.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after buying an additional 85 shares during the period. Northwestern Mutual Wealth Management Co. lifted its holdings in United Therapeutics by 18.8% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock worth $127,000 after buying an additional 70 shares during the period. Jump Financial LLC acquired a new position in United Therapeutics during the 2nd quarter worth about $277,000. Cerity Partners LLC lifted its holdings in United Therapeutics by 77.3% during the 2nd quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock worth $3,691,000 after buying an additional 5,600 shares during the period. Finally, Bank of Nova Scotia lifted its holdings in United Therapeutics by 6.9% during the 2nd quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock worth $468,000 after buying an additional 105 shares during the period. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.